PMID- 34261116
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20231107
IS  - 1531-6963 (Electronic)
IS  - 1040-8711 (Print)
IS  - 1040-8711 (Linking)
VI  - 33
IP  - 5
DP  - 2021 Sep 1
TI  - Clinical features of multisystem inflammatory syndrome in children.
PG  - 378-386
LID - 10.1097/BOR.0000000000000818 [doi]
AB  - PURPOSE OF REVIEW: To review diagnosis, clinical characteristics and treatment of 
      multisystem inflammatory syndrome in children (MIS-C) associated with severe 
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RECENT FINDINGS: MIS-C 
      emerged in spring 2020 as a hyperinflammatory syndrome following SARS-CoV-2 
      exposure in children. Despite growing awareness of MIS-C, diagnosis remains 
      challenging due to the range of phenotypes and severity. Fever accompanied by 
      shock, cardiac dysfunction, gastrointestinal symptoms, or mucocutaneous signs 
      suggestive of Kawasaki disease, especially in the presence of known or suspected 
      coronavirus disease 2019 exposure, should trigger consideration of MIS-C. 
      However, clinical presentations are highly varied and may overlap with other 
      infectious diseases. Clinicians must maintain a high index of suspicion for MIS-C 
      and be aware that patients may develop coronary artery aneurysms and myocarditis 
      even with few or no Kawasaki disease symptoms. More precise diagnostic criteria 
      and specific biomarkers are needed to aid diagnosis. Intravenous immunoglobulin 
      (IVIG) is first-line therapy, and steroids should be considered as initial 
      adjunctive treatment for patients with severe manifestations or other risk 
      factors. Prompt treatment is essential, as patients may worsen acutely, though 
      overall prognosis is reassuring. SUMMARY: MIS-C associated with SARS-CoV-2 has 
      varied clinical manifestations. Clinicians must be aware of the common 
      presentation and potential for decompensation and cardiac sequalae to guide 
      appropriate evaluation and treatment.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Roberts, Jordan E
AU  - Roberts JE
AD  - Division of Immunology, Boston Children's Hospital, Harvard Medical School, 
      Boston, Massachusetts, USA.
FAU - Henderson, Lauren A
AU  - Henderson LA
LA  - eng
GR  - K08 AR073339/AR/NIAMS NIH HHS/United States
GR  - P30 AR070253/AR/NIAMS NIH HHS/United States
GR  - T32 AI007512/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
RN  - pediatric multisystem inflammatory disease, COVID-19 related
SB  - IM
MH  - *COVID-19
MH  - Humans
MH  - *Mucocutaneous Lymph Node Syndrome/diagnosis/epidemiology/therapy
MH  - SARS-CoV-2
MH  - Systemic Inflammatory Response Syndrome
PMC - PMC8445592
MID - NIHMS1719769
COIS- There was no additional assistance, and the authors have no conflicts of interest 
      to declare.
EDAT- 2021/07/15 06:00
MHDA- 2021/10/05 06:00
PMCR- 2022/09/01
CRDT- 2021/07/14 20:13
PHST- 2021/07/15 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
PHST- 2021/07/14 20:13 [entrez]
PHST- 2022/09/01 00:00 [pmc-release]
AID - 00002281-202109000-00003 [pii]
AID - 10.1097/BOR.0000000000000818 [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 2021 Sep 1;33(5):378-386. doi: 10.1097/BOR.0000000000000818.